| Company Name: |
Xi'an Minze Pharmaceutical Technology Co., Ltd
|
| Tel: |
13981836672 |
| Email: |
2560370848@qq.com |
| Products Intro: |
Product Name:N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-, sodium salt (1:1)
CAS:1119276-80-0
Purity:95 Package:0.5g;1g;5g;10g;25g;50g;100g;1kg
|
Sodium Lifitegrast manufacturers
|
| | Sodium Lifitegrast Basic information |
| Product Name: | Sodium Lifitegrast | | Synonyms: | Sodium Lifitegrast;N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-, sodium salt (1:1);SAR 1118-023;Lifitegrast sodium;LIFITEGRAST SODIUM; SAR-1118-023; SAR 1118-023; SAR1118-023; XIIDRA;Xiidra | | CAS: | 1119276-80-0 | | MF: | C29H25Cl2N2NaO7S | | MW: | 639.48 | | EINECS: | | | Product Categories: | | | Mol File: | 1119276-80-0.mol |  |
| | Sodium Lifitegrast Chemical Properties |
| solubility | Acetonitrile: Slightly soluble
DMSO: Soluble
Water: Slightly soluble | | form | Solid | | color | Light yellow to yellow |
| | Sodium Lifitegrast Usage And Synthesis |
| Uses | Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease[1]. | | in vivo | Lifitegrast has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior[2]. | | IC 50 | αLβ2 | | References | [1] Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15. DOI:10.1016/j.jtos.2016.01.001
[2] Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. DOI:10.1089/jop.2012.0102
[3] Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin(STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5198-204. DOI:10.1167/iovs.09-5144
[4] MIN ZHONG*. Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye[J]. ACS Medicinal Chemistry Letters, 2012, 3 3: 203-206. DOI: 10.1021/ml2002482
[5] CHRISTOPHER J MURPHY. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.[J]. Investigative ophthalmology & visual science, 2011, 52 6: 3174-3180. DOI: 10.1167/iovs.09-5078 |
| | Sodium Lifitegrast Preparation Products And Raw materials |
|